Products

  1. Home
  2. Products
  3. Bone & Mineral Metabolism
  4. IDKmonitor® Adalimumab Free ADA ELISA (Health Canada)

IDKmonitor® Adalimumab Free ADA ELISA (Health Canada)

Method: ELISA
Sample Type (Matrix): Serum, EDTA Plasma
Sample Volume: 25 µL
Species: Human
Incubation time: 1h 10m
Size: 96 wells
Regulatory Status: Health Canada Licensed. Not for sale in the U.S.
Kit Manual: Download

The IDKmonitor® Adalimumab Free ADA ELISA is for the detection of free anti-drug antibodies against Adalimumab (e.g., HUMIRA®) and measures free anti-Adalimumab antibodies in EDTA plasma and serum.

Health Canada Licensed. For Laboratory Professional Use Only.

Not for sale in the U.S. Please contact us to order or get a quote.

If you are in the U.S., you can purchase the RUO version of the Adalimumab Free ADA ELISA.

Browse our other IDKmonitor® Adalimumab ELISAs.

Test Principle of the IDKmonitor® Adalimumab Free ADA ELISA

The IDKmonitor® Adalimumab Free ADA ELISA is a sandwich assay for the determination of free antibodies against adalimumab (e. g. HUMIRA®). In the first incubation step, the free antitherapeutic antibodies from the sample are bound to the adalimumab F(ab)2 fragments coated on the plate. To remove all unbound substances, a washing step is carried out. In a further incubation step, peroxidase-labeled adalimumab is added. After another washing step to remove all unbound substances, the solid phase is incubated with the substrate, Tetramethylbenzidine (TMB). An acidic stop solution is then added.

The color converts to yellow. The absorbance of the color compound is determined photometrically. The intensity of the color is directly proportional to the amount of bound ADAs (here: anti-adalimumab antibodies) from the sample. The results are evaluated by a cut-off control.

 

Additional information

Weight 35.5 oz
Dimensions 6.5 × 10 × 4.5 in
Social media & sharing icons powered by UltimatelySocial

Become an IDK Insider!

Join our mailing list to receive the latest news and updates from Immundiagnostik, Inc.

 
 
 
 

You have Successfully Subscribed!